🇺🇸 FDA
Patent

US 10508103

Benzimidazole-linked indole compound acting as novel divalent IAP antagonist

granted A61KA61K31/4184A61P

Quick answer

US patent 10508103 (Benzimidazole-linked indole compound acting as novel divalent IAP antagonist) held by Medshine Discovery Inc. expires Mon Dec 12 2039 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
Medshine Discovery Inc.
Grant date
Tue Dec 17 2019 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Dec 12 2039 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
32
CPC classes
A61K, A61K31/4184, A61P, A61P31/20, A61P35/00